Publications

Saul Karpen, Greg Wright, Philip Stein, Patrick Horn
The BOLD Study: A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Infants With Biliary Atresia After Kasai Portoenterostomy
Journal of Pediatric Gastroenterology and Nutrition. 2020; 71(1):S435-436. doi: 10.1097/MPG.0000000000002966

Philip Stein, Greg Wright, Lise Kjems, Patrick Horn
Drug-Drug Interaction Study to Evaluate the Interaction of A4250 (Odevixibat) with Itraconazole, a P-gp Inhibitor in Healthy Adult Subjects
Journal of Pediatric Gastroenterology and Nutrition. 2020; 71(1):S433-335. doi: 10.1097/MPG.0000000000002966

Saul J Karpen, Deirdre Kelly, Cara Mack, Philip Stein
Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders
Hepatology International (2020); doi: 10.1007/s12072-020-10070-w

Binita M. Kamath, Philip Stein, Roderick H. J. Houwen , Henkjan J. Verkade
Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis
Liver International 2020;00:1–11.doi:10.1111/liv.14553

Christoph Slavetinsky, Ekkehard Sturm
Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis
BMJ Case Rep 2020;13:e234185.doi:10.1136/bcr-2019- 234185

Ekkehard Sturm et al.
The ileal bile acid transport inhibitor odevixibat reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple-dose, open-label, multinational study
Hepatology 2017; 66: 646-47 (Suppl. 1). doi: 10.1002/hep.29501

Graffner, P.-G. Gillberg, L. Rikner and H.-U. Marschall
The ileal bile acid transporter inhibitor odevixibat decreases serum bile acids by interrupting the enterohepatic circulation
Aliment Pharmacol Ther 2016; 43: 303-310. doi: 10.1111/apt.13457

Anna Baghdasaryan et al.
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
Journal of Hepatology 2016; 64: 674–681. doi: 10.1016/j.jhep.2015.10.024

Per-Göran Gillberg, Erik Lindström, Taishi Hashiguchi, Yuka Shirakata, Yuya Fukui, Jan P Mattsson.
Inhibition of the ileal bile acid transporter (IBAT) by odevixibat reduces hepatic damage in a mouse model of nonalcoholic steatohepatitis (NASH)
Gastroenterology 2016; 150: S1091. doi: 10.1016/S0016-5085(16)33683-6

Mats Rudling, Michael Camilleri, Hans Graffner, Jens Juul Holst and Leif Rikner
Specific inhibition of bile acid transport alters plasma lipids and GLP-1
BMC Cardiovascular Disorders 2015; 15:75 doi: 10.1186/s12872-015-0070-9

Banny S Wong and Michael Camilleri
Elobixibat for the treatment of constipation
Expert Opin. Investig. Drugs (2013) 22(2):277-284 doi: 10.1517/13543784.2013.753056

William D. Chey, Michael Camilleri, Lin Chang, Leif Rikner and Hans Graffner.
Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
Am J Gastroenterol, 2011; 106: 1803-12 doi: 10.1038/ajg.2011.162

Banny S. Wong, Michael Camilleri, Sanna McKinzie, Duane Burton, Hans Graffner and Alan R. Zinsmeister
Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation
Am J Gastroenterol. 2011; 106:2154–2164 doi: 10.1038/ajg.2011.285

Simrén, A. Bajor, P.-G. Gillberg, M. Rudling and H. Abrahamsson
Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study
Aliment Pharmacol Ther 2011; 34: 41–50 doi: 10.1111/j.1365-2036.2011.04675.x

Per-Göran Gillberg, Mikael Dahlström, Ingemar Starke, Ann-Margret Östlund-Lindqvist
The IBAT Inhibition by A3309 – A Potential Mechanism for the Treatment of Constipation
Gastroenterology 2010; 138: S224 

RN Appleby, A Bajor, P-G Gillberg, H Graffner, M Simrén, KA Ung and JRF Walters
Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhea
United European Gastroenterology Journal 2016; Online version available (ueg.sagepub.com) doi: 10.1177/2050640616662432

Leonardo Ruiz, et al.
The PICTURE Burden of Illness Study: Quantifying the Socio-economic Burden of Progressive Familial Intrahepatic Cholestasis (PFIC) in the US, UK, France and Germany
Journal of Pediatric Gastroenterology and Nutrition. 2020; 71(1):S100-101. doi: 10.1097/MPG.0000000000002966

Peter Åkerblad, et al.
A3907, a Novel Inhibitor of Bile Acid Transport in the Intestine and Kidney, Improves Markers of Metabolic and Hepatic Pathology, and Reduces Nonalcoholic Fatty Liver Disease Activity Score and Fibrosis Stage in a Diet-induced and Biopsy-confirmed Mouse Model of Nonalcoholic Steatohepatitis
Hepatology. 2020; 72 (1): S315-316. doi:10.1002/hep.31579

Per-Göran Gillberg, et al.
Discovery and Characterization of Novel Bile Acid Transporter Inhibitors with Potential for Treatment of Liver Diseases
Hepatology. 2020; 72 (1): S226-227. doi:10.1002/hep.31579

Henkjan J. Verkade, et al.
Systematic Review and Meta-Analysis: Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis
Journal of Pediatric Gastroenterology and Nutrition 2020;doi:10.1097/MPG.0000000000002789

Daan B.E. van Wessel, et al.
Genotype correlates with the natural history of severe bile salt export pump deficiency
Journal of Hepatology 2020;73:84–93.doi:10.1016/j.jhep.2020.02.007

Stéphanie Da Silva, Åsa V. Keita, Sofie Mohlin, Sven Pahlman, Ingrid Pahlman, Johan D. Söderholm
A novel PPARγ agonist, AS002, induces PPARγ-activity in ulcerative colitis mucosa, and prevents and reverses inflammation in DSS colitis.
United European Gastroenterology Journal 2015; 3 (5 suppl.)